短期局部重组人神经生长因子(rhNGF)用于青光眼神经增强的1b期随机对照研究:安全性、耐受性与疗效评估
这项前瞻性、1b期、单中心、随机、双盲、载体对照、平行组研究纳入60例开角型青光眼患者,按40:20随机接受180 μg/mL rhNGF或载体滴眼液双眼每日3次共8周,并随访24周。结果显示无治疗相关严重不良事件,耐受性良好,但 Humphrey视野全局指数与RNFL厚度组间无统计学显著差异。作者结论认为rhNGF安全可耐受,虽未检出短期神经增强,但基于临床前强效作用及本研究趋势,有必要开展神经保护试验进行疗效分析。
要点
- 180 μg/mL rhNGF双眼每日3次共8周,无治疗相关严重不良事件及药物相关全身毒性。
- 治疗组眼周疼痛52% vs 载体组5%,7.5%因不适停药,2.5%提前退出研究。
- Humphrey视野全局指数与RNFL厚度组间无统计学显著差异,趋势利于rhNGF。
核心结论
- 局部180 μg/mL rhNGF安全且可耐受。
- 本试验未检出统计学显著的短期神经增强,但鉴于NGF在临床前模型中的强效作用及本研究观察到的趋势,有必要开展神经保护试验进行疗效分析。
研究设计与样本
- 前瞻性、1b期、单中心、随机、双盲、载体对照、平行组研究(clinicaltrials.gov NCT02855450)。
- 共60例开角型青光眼患者按40:20随机接受180 μg/mL rhNGF或载体对照滴眼液双眼给药,每日3次共8周,治疗后随访24周。
- 正式选择一只眼为研究眼,但双眼均接受研究和给药。
- 主要终点为安全性(不良事件评估)与耐受性(患者报告结局评估)。
- 次要结局包括基线、治疗8周后及治疗后4周和24周(总计12周和32周)的最佳矫正视力、Humphrey视野、视网膜电图和光学相干断层扫描视网膜神经纤维层厚度。
主要发现
- 60例随机患者中23例为女性(38%),平均年龄66.1岁。
- 截至第32周,无治疗相关严重不良事件,包括无意外严重视神经病变进展、无影响眼功能或眼压的不良事件、无药物相关全身毒性。
- 局部高剂量rhNGF耐受良好,症状负担低,主要引起眼周疼痛(治疗组52% vs 载体组5%),仅3例患者(7.5%)因不适停止治疗,其中1例患者(2.5%)提前退出研究。
- Humphrey视野全局指数组间无统计学显著差异,视网膜神经纤维层总厚度、象限厚度或钟点厚度组间无有意义差异,但功能和结构指标均显示利于rhNGF的非显著趋势。
- 使用真实世界参与者数据生成后续研究所需样本量的估计。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本试验未检出统计学显著的短期神经增强。
- 功能和结构指标仅显示利于rhNGF的非显著趋势。
- 作者结论指出有必要开展神经保护试验进行疗效分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: No approved therapies directly target retinal ganglion cells (RGCs) for neuroprotection or neuroenhancement in glaucoma. Recombinant human nerve growth factor (rhNGF) has been shown to promote RGC survival and function in animal models of optic neuropathy. Here we evaluate the safety, tolerability, and efficacy of short-term, high-dose rhNGF eye drops versus placebo in a cohort of glaucoma patients. DESIGN: This was a prospective, phase 1b, single-center, randomized, double-masked, vehicle-controlled, parallel-group study. METHODS: This study was designed to assess safety and tolerability as well as short-term neuroenhancement of structure and function (clinicaltrials.gov NCT02855450). A total of 60 open-angle glaucoma patients were randomized 40:20 to receive either 180 μg/mL rhNGF or vehicle control eye drops in both eyes, 3 times daily for 8 weeks, with a 24-week post-treatment follow-up. One eye was officially selected as the study eye, although both eyes were studied and dosed. Primary endpoints were safety, as assessed by adverse events, and tolerability, as assessed by patient-reported outcomes. Secondary outcome measures included best corrected visual acuity (BCVA), Humphrey visual field, electroretinograpy (ERG), and optical coherence tomography (OCT) of retinal nerve fiber layer (RNFL) thickness at baseline, after 8 weeks of treatment, and at 4 and 24 weeks after treatment (12 and 32 weeks total). RESULTS: Of the 60 randomized patients, 23 were female (38%) and the average age was 66.1 years. Through week 32, there were no treatment-related serious adverse events, including no unexpectedly severe progression of optic neuropathy, no adverse events affecting ocular function or pressure, and no drug-related systemic toxicity. Topical high-dose rhNGF was tolerated well, with a low level of symptom burden mainly eliciting periocular ache (in 52% of treated group and 5% of placebo group) and only 3 patients (7.5%) discontinuing treatment because of discomfort, of whom 1 patient (2.5%) prematurely withdrew from the study. There were no statistically significant differences in global indices of Humphrey visual field and no meaningful differences in total, quadrant, or clock-hour mean RNFL thickness between the groups, although both of these function and structure measures showed nonsignificant trends toward significance in favor of rhNGF. Real-world participant data was used to generate an estimate of cohort size needed to power subsequent studies. CONCLUSIONS: Use of rhNGF is safe and tolerable in a topical 180-μg/mL formulation. Although no statistically significant short-term neuroenhancement was detected in this trial, given the strong effects of NGF in preclinical models and the trends detected in this study, analysis for efficacy in a neuroprotection trial is warranted. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
引用
- Beykin G, Stell L, Halim MS, et al. Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol. 2021. PMID: 34780798. doi:10.1016/j.ajo.2021.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。